Pancreatic cancer is the fourth leading cause of cancer deaths in the United States each year, in part because around four-fifths of cases go undetected until they have reached an advanced stage. But a new, biomarker-based test could soon change all that — and offer a way to monitor treatment outcomes.
Long before they develop neurofibrillary tangles or beta-amyloid plaques, brains with Alzheimer’s disease begin experiencing problems in their cells’ power plants — the mitochondria — that hinder their ability to make energy for cells.
Declines in gene expression related to mitochondria can occur in subjects as young as their early 30s.
Scientists have identified drug targets that could one day make pancreatic cancer less painful — and more survivable — by knocking out key molecular signals. The signals form an essential part of the process by which cancer cells invade and spread through nearby nerves, wounding nerve endings.
Read/listen to my full story at KJZZ’s Arizona Science Desk:
Seventy-plus years into the Atomic Age, the United States still lacks a good radiation-dosage test.
But the ASU Radiation Biodosimetry Test (ARad), a device being developed by Arizona State University’s Biodesign Institute, could soon help doctors triage victims of a nuclear attack by gauging their exposure to ionizing radiation via changes in gene expression.
ARad is one of only a few tests under development that can detect radiation exposure levels. Read/listen to my full story at KJZZ’s Arizona Science Desk:
It’s said that we all have a double somewhere in the world. It’s a haunting thought, but almost comforting compared to the harrowing tales of identity theft we hear on the nightly news. But, hey, we live in the age of fingerprints, DNA and CSI, right? The post-911 world of ever-more Orwellian identification requirements? Surely we’ve left cases of mistaken identity firmly in the past.